Companies sponsors |
Novartis (ruxolitinib) |
|
Royal College of Physicians |
Others |
Department of Health and Social Care |
|
NHS England |
|
Welsh Government |
Patient carer groups |
Blood Cancer UK |
|
Leukaemia CARE |
|
MPN Voice |
Associated public health groups |
None |
Comparator companies |
Aspen Pharma Trading (busulfan) - confidentially agreement not signed, not participating |
|
Aspire Pharma (peginterferon alfa-2a) - confidentially agreement not signed, not participating |
|
Aurobindo Pharma-Milpharm (anagrelide) - confidentially agreement not signed, not participating |
|
Bristol-Myers Squibb (hydroxycarbamide) - confidentially agreement not signed, not participating |
|
Dr Reddy’s Laboratories (anagrelide) - confidentially agreement not signed, not participating |
|
Glenmark Pharmaceuticals (anagrelide) - confidentially agreement not signed, not participating |
|
Kent Pharma (anagrelide) - confidentially agreement not signed, not participating |
|
Medac (hydroxycarbamide) - confidentially agreement not signed, not participating |
|
Mylan (anagrelide) - confidentially agreement not signed, not participating |
|
Sandoz (anagrelide) - confidentially agreement not signed, not participating |
|
Takeda UK (anagrelide) - confidentially agreement not signed, not participating |
|
Zentiva (anagrelide) - confidentially agreement not signed, not participating |
General commentators |
Department of Health, Social Services and Public Safety for Northern Ireland |
|
Healthcare Improvement Scotland |
|
Medicines and Healthcare products Regulatory Agency |
|
Scottish Medicines Consortium |
|
Welsh Health Specialised Services Committee |
Relevant research groups |
National Institute for Health Research |